Alnylam, will focus on AMD and other ocular diseases caused by abnormal growth or leakage of small blood vessels in the eye.Alnylam's existing program to develop a direct RNAi therapeutic for the treatment of AMD will now be incorporated into the new collaboration.Under the terms of the agreement, Alnylam will receive an initial cash payment from Merck and can receive additional cash payments upon